Related Experiment Video
Updated: Jan 13, 2026
Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
Published on: January 14, 2014
IDH1 and ATRX mutations synergistically modulate cell proliferation and ferroptosis in glioblastoma cells
Siqi Liu1, Xiangnan Xiao2, Ang Li2
1Department of Pathophysiology, School of Basic Medical Sciences, Anhui Medical University Hefei, Anhui, China.
Abstract:
IDH1 and ATRX mutations frequently co-occur in several glioma subtypes, including secondary glioblastomas (GBMs), suggesting that these alterations may function cooperatively during tumor development. However, the molecular basis of their interaction remains poorly defined. In present study, we demonstrate that the IDH1-R132H mutation acts synergistically with ATRX loss to upregulate pro-proliferative genes while suppressing interferon (IFN) signaling. This coordinated effect supports the notion that the two mutations jointly promote tumor growth and attenuate anti-tumor immune responses. Notably, we also found that the combined IDH1/ATRX mutations increase GBM cell sensitivity to various forms of cell death, particularly ferroptosis. Mechanistically, the dual IDH1/ATRX alteration upregulates pro-ferroptotic genes (HMOX1 and ACSL4) while downregulating anti-ferroptotic genes (SLC7A11 and GPX4), thereby sensitizing GBM cells to ferroptosis induction. Together, our findings provide new biological insights into IDH1/ATRX-driven GBM pathogenesis and highlight ferroptosis as a potential therapeutic vulnerability in this aggressive tumor subtype.
Insights
Mutations in IDH1 and ATRX cooperate to drive glioma growth by promoting proliferation and suppressing immune responses. This dual mutation also sensitizes glioblastoma cells to ferroptosis, a form of cell death.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- IDH1 and ATRX mutations frequently co-occur in glioma, particularly secondary glioblastomas (GBMs).
- The cooperative molecular mechanisms underlying IDH1 and ATRX alterations in tumor development are not well understood.
Purpose of the Study:
- To investigate the synergistic effects of IDH1-R132H mutation and ATRX loss in glioma pathogenesis.
- To elucidate the molecular basis of IDH1/ATRX cooperation in promoting tumor growth and immune evasion.
- To explore the impact of combined IDH1/ATRX mutations on glioblastoma cell death pathways, specifically ferroptosis.
Main Methods:
- Investigated the functional interaction between IDH1-R132H mutation and ATRX loss in glioma models.
- Analyzed the regulation of pro-proliferative and interferon signaling pathways.
- Assessed changes in cell death sensitivity, focusing on ferroptosis.
- Examined the expression of key ferroptosis-related genes (HMOX1, ACSL4, SLC7A11, GPX4).
Main Results:
- IDH1-R132H mutation and ATRX loss synergistically upregulate pro-proliferative genes and suppress interferon signaling.
- The combined mutations promote glioma growth and attenuate anti-tumor immune responses.
- GBM cells with combined IDH1/ATRX mutations exhibit increased sensitivity to ferroptosis.
- This sensitization is mediated by the upregulation of pro-ferroptotic genes (HMOX1, ACSL4) and downregulation of anti-ferroptotic genes (SLC7A11, GPX4).
Conclusions:
- IDH1 and ATRX mutations cooperate to drive GBM pathogenesis through enhanced proliferation and immune suppression.
- Combined IDH1/ATRX alterations create a vulnerability to ferroptosis in glioblastoma.
- Targeting ferroptosis pathways may represent a promising therapeutic strategy for IDH1/ATRX-mutant GBM.
Related Concept Videos
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...